Result of AGM.


    27 June 2025 12:27:30
  • Source: Sharecast
RNS Number : 7888O
Cambridge Cognition Holdings PLC
27 June 2025
 

27 June 2025

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Result of AGM

 

Cambridge Cognition Holdings plc, the brain health software group specialising in digital health products that advance brain health research and treatment, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.

 

Proxy votes were received in respect of 67.6% of the Company's issued share capital. The votes cast were as follows:

 

 

Resolution

Votes For

Percent of votes cast For

Votes Against

Percent of votes cast Against

Votes Withheld

1

To approve the 2024 Report and Accounts

28,372,450

100%

-

-

-

2

To approve the 2024 Directors' Remuneration Report1

28,346,127

99.91%

25,315

0.09%

1,008

3

To approve the Directors' Remuneration Policy1

28,346,127

99.91%

25,315

0.09%

1,008

4

To re-appoint the auditors

28,359,763

99.99%

3,500

0.01%

9,187

5

To authorise the directors to set the auditors' remuneration

28,370,475

100%

-

-

1,975

6

To re-elect Steven Powell as a director

28,369,043

100%

-

-

3,407

7

To re-elect Richard Bungay as a director

24,074,907

100%

-

-

4,297,543

8

To re-elect Stuart Gall as a director

28,371,018

100%

-

-

1,432

9

To re-elect Debra Leeves as a director

24,074,907

100%

-

-

4,297,543

10

To re-elect Nick Rodgers as a director

28,371,018

100%

-

-

1,432

11

To elect Jon Kempster as a director

28,371,018

100%

-

-

1,432

12

Authority to allot shares

28,340,996

99.89%

30,446

0.11%

1,008

13

Authority to disapply pre-emption rights2

28,323,483

99.83%

47,959

0.17%

1,008

14

Authority to purchase own shares on the market2

24,925,895

99.84%

39,143

0.16%

3,407,412

 

 

Notes

1.  Indicates an advisory vote.

2.  Indicates a Special Resolution requiring 75% of votes cast to be carried.

 

 

Enquiries:

 

 

Cambridge Cognition Holdings plc

 

Tel: 012 2381 0700

Rob Baker, Joint Managing Director

and Chief Operating Officer

press@camcog.com

 





 


Panmure Liberum Limited (NOMAD and Joint Broker)

Tel: 020 7886 2968

Freddy Crossley / Will Goode / Mark Rogers

(Corporate Finance)

Rupert Dearden

(Corporate Broking)

 

 


Dowgate Capital Limited (Joint Broker)

Tel: 020 3903 7715

David Poutney / Amber Higgs




Hudson Sandler (Financial PR and IR)

Dan de Belder / Hattie Dreyfus / Jackson Redley

 

Tel: 020 7796 4133

cog@hudsonsandler.com



 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

 

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

 

For further information, visit: www.cambridgecognition.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGPKOBBDBKDPAB

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.